A testable framework integrates platelet engineering and injectable hydrogels with CAR T cells for localized treatment of microscopic residual disease after breast cancer surgery.
8 affiliations
- 1Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.
- 2Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.
- 3Ajyal Al Marefaah International School, Ministry of Education, Jazan, Saudi Arabia.
- 4Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia.
- 5Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran. [email protected].
- 6Department of Basic Medical Sciences, Khoy University of Medical Sciences, Khoy, Iran. [email protected].
- 7Laser Research Center, University of Johannesburg, Doornfontein, 2028, South Africa. [email protected].
- 8Department of Medical Laboratory Sciences, School of Allied Medical Sciences, Mazandaran University of Medical Sciences, Sari, Iran. [email protected].
Abstract
Postoperative recurrence remains a major cause of treatment failure in breast cancer, largely because microscopic residual disease persists within a biologically active surgical niche characterized by inflammation, immune suppression, and spatially irregular tumor beds. In this review, we critically evaluate whether combining a precisely defined platelet-derived module, an injectable hydrogel, and CAR-T cells can provide nonredundant advantages over standard treatment and simpler local or pairwise alternatives in postoperative breast cancer. Platelet-inspired delivery systems exploit endogenous injury-homing and adhesion biology to improve localization to damaged vasculature and disease-relevant tissue, while hydrogels provide cavity-conformal retention, prolonged local release, and spatial control of therapeutic exposure within irregular surgical beds. CAR-T cells confer antigen-directed cytotoxicity to eliminate residual malignant cells that survive surgery and conventional adjuvant treatment. Importantly, the supporting evidence is tiered rather than uniform. Most studies have evaluated individual modules or selected pairwise combinations that directly support functions such as injury-associated localization, local retention, or antigen-directed cytotoxicity. Direct evidence of postoperative breast cancer is currently limited to intact platelet-B7-H3 CAR-T conjugates, a pairwise product that contains neither an injectable hydrogel nor a platelet-membrane-coated nanocarrier. The closest three-component precedent used a hyaluronic acid hydrogel to co-deliver CSPG4-directed CAR-T cells, IL-15-loaded polymer nanoparticles, and intact anti-PD-L1-conjugated platelets after resection of subcutaneous human melanoma in NSG mice. No published study has directly tested this defined platelet-membrane-coated nanocarrier-hydrogel-CAR-T product in postoperative breast cancer; therefore, interpret the construct discussed here as a hypothesis-driven, critical design perspective rather than a validated, disease-specific platform. We further discuss the potential of this integrated approach to improve control of microscopic disease within or immediately adjacent to the surgical bed and to remodel the local postoperative immune microenvironment. However, effects on regional nodal or distant relapse remain unproven and would require integration with regional radiotherapy and subtype-directed systemic therapy. Finally, we highlight the major barriers that must be resolved before clinical translation, including platelet-associated thrombogenicity, off-target biodistribution, CAR-T trafficking and persistence, antigen heterogeneity, manufacturability, and the need for predictive biomarker-guided patient selection. Collectively, this review reframes the postoperative breast cancer bed as a programmable therapeutic microenvironment and outlines a rational roadmap for next-generation adjuvant immunoengineering.
Related
- Thermal Phase Behavior of PNIPAM-Based Hydrogels: Different Scenarios and Implications in Injectable Hydrogel Design.
- Injectable Conductive Hydrogels as Multifunctional Bioactive Soft Interfaces for Skeletal Muscle Regeneration.
- Injectable bioactive glass hydrogels orchestrate metalloimmunotherapy by depleting pathogenic B cells and rescuing bone in rheumatoid arthritis
- Intranasal hydrogels for Alzheimer’s disease: from nasal-interface engineering to brain targeting and translational readiness
- Chlorophyll as a sustainable crosslinking strategy for engineering highly compressible hydrogels.
BibTeX
@article{heydari2026testable,
title = {{A testable framework integrates platelet engineering and injectable hydrogels with CAR T cells for localized treatment of microscopic residual disease after breast cancer surgery.}},
author = {Farshad Heydari and Mohammed S Alqassimi and Nasrin Mansuri and Mehdi Derakhshani and Michael R Hamblin and Jalal Naghinezhad},
journal = {Discover nano},
year = {2026},
month = nov,
doi = {10.1186/s11671-026-05095-3},
url = {https://europepmc.org/article/MED/42970186},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - A testable framework integrates platelet engineering and injectable hydrogels with CAR T cells for localized treatment of microscopic residual disease after breast cancer surgery.
AU - Farshad Heydari
AU - Mohammed S Alqassimi
AU - Nasrin Mansuri
AU - Mehdi Derakhshani
AU - Michael R Hamblin
AU - Jalal Naghinezhad
PY - 2026
DA - 2026/11/02
JO - Discover nano
DO - 10.1186/s11671-026-05095-3
UR - https://europepmc.org/article/MED/42970186
AB - Postoperative recurrence remains a major cause of treatment failure in breast cancer, largely because microscopic residual disease persists within a biologically active surgical niche characterized by inflammation, immune suppression, and spatially irregular tumor beds. In this review, we critically evaluate whether combining a precisely defined platelet-derived module, an injectable hydrogel, and CAR-T cells can provide nonredundant advantages over standard treatment and simpler local or pairwise alternatives in postoperative breast cancer. Platelet-inspired delivery systems exploit endogenous injury-homing and adhesion biology to improve localization to damaged vasculature and disease-relevant tissue, while hydrogels provide cavity-conformal retention, prolonged local release, and spatial control of therapeutic exposure within irregular surgical beds. CAR-T cells confer antigen-directed cytotoxicity to eliminate residual malignant cells that survive surgery and conventional adjuvant treatment. Importantly, the supporting evidence is tiered rather than uniform. Most studies have evaluated individual modules or selected pairwise combinations that directly support functions such as injury-associated localization, local retention, or antigen-directed cytotoxicity. Direct evidence of postoperative breast cancer is currently limited to intact platelet-B7-H3 CAR-T conjugates, a pairwise product that contains neither an injectable hydrogel nor a platelet-membrane-coated nanocarrier. The closest three-component precedent used a hyaluronic acid hydrogel to co-deliver CSPG4-directed CAR-T cells, IL-15-loaded polymer nanoparticles, and intact anti-PD-L1-conjugated platelets after resection of subcutaneous human melanoma in NSG mice. No published study has directly tested this defined platelet-membrane-coated nanocarrier-hydrogel-CAR-T product in postoperative breast cancer; therefore, interpret the construct discussed here as a hypothesis-driven, critical design perspective rather than a validated, disease-specific platform. We further discuss the potential of this integrated approach to improve control of microscopic disease within or immediately adjacent to the surgical bed and to remodel the local postoperative immune microenvironment. However, effects on regional nodal or distant relapse remain unproven and would require integration with regional radiotherapy and subtype-directed systemic therapy. Finally, we highlight the major barriers that must be resolved before clinical translation, including platelet-associated thrombogenicity, off-target biodistribution, CAR-T trafficking and persistence, antigen heterogeneity, manufacturability, and the need for predictive biomarker-guided patient selection. Collectively, this review reframes the postoperative breast cancer bed as a programmable therapeutic microenvironment and outlines a rational roadmap for next-generation adjuvant immunoengineering.
SN - 2731-9229
ER -